Phase I study of DMT-210 in patients with moderate-to-severe acne rosacea.

Trial Profile

Phase I study of DMT-210 in patients with moderate-to-severe acne rosacea.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs DMT 200 (Primary)
  • Indications Rosacea
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 28 Sep 2016 28-day top-line results published in Dermata Therapeutics media release.
    • 30 May 2016 New trial record
    • 16 May 2016 According to Dermata Therapeutics media release, the company plans to have top line results in the third quarter of this year (2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top